TW200613032A - Uses for augmenting bone - Google Patents

Uses for augmenting bone

Info

Publication number
TW200613032A
TW200613032A TW094120300A TW94120300A TW200613032A TW 200613032 A TW200613032 A TW 200613032A TW 094120300 A TW094120300 A TW 094120300A TW 94120300 A TW94120300 A TW 94120300A TW 200613032 A TW200613032 A TW 200613032A
Authority
TW
Taiwan
Prior art keywords
pyk2
bone
agent
optionally
determining
Prior art date
Application number
TW094120300A
Other languages
English (en)
Inventor
Thomas Aquinas Brown
Leonard Buckbinder
Angel Guzman-Perez
John Charles Kath
Hua-Zhu Ke
Lisa Maria Olson
Michael Joseph Luzzio
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of TW200613032A publication Critical patent/TW200613032A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW094120300A 2004-06-21 2005-06-17 Uses for augmenting bone TW200613032A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58140704P 2004-06-21 2004-06-21

Publications (1)

Publication Number Publication Date
TW200613032A true TW200613032A (en) 2006-05-01

Family

ID=35240963

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094120300A TW200613032A (en) 2004-06-21 2005-06-17 Uses for augmenting bone

Country Status (9)

Country Link
US (1) US20090118316A1 (zh)
EP (1) EP1765461A1 (zh)
JP (1) JP2008503561A (zh)
AR (1) AR049922A1 (zh)
BR (1) BRPI0512342A (zh)
CA (1) CA2571482A1 (zh)
MX (1) MXPA06015170A (zh)
TW (1) TW200613032A (zh)
WO (1) WO2005123191A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9402852B2 (en) * 2006-10-20 2016-08-02 Children's Medical Center Corporation Method to enhance tissue regeneration
ES2472323T3 (es) 2008-06-17 2014-06-30 Astrazeneca Ab Compuestos de piridina
AU2009308191A1 (en) 2008-10-24 2010-04-29 Warsaw Orthopedic, Inc. Compositions and methods for promoting bone formation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254595A (en) * 1988-12-23 1993-10-19 Elf Sanofi Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them
US5837815A (en) * 1994-12-15 1998-11-17 Sugen, Inc. PYK2 related polypeptide products
US5837524A (en) * 1994-12-15 1998-11-17 Sugen, Inc. PYK2 related polynucleotide products
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
UA51676C2 (uk) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
UA59384C2 (uk) * 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
AU6163398A (en) * 1997-02-11 1998-08-26 Merck & Co., Inc. Identification of inhibitors of protein tyrosine kinase 2
US6124314A (en) * 1997-10-10 2000-09-26 Pfizer Inc. Osteoporosis compounds
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
US20030191162A1 (en) * 1998-12-31 2003-10-09 Sugen Inc. 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy
WO2004056807A1 (en) * 2002-12-20 2004-07-08 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth

Also Published As

Publication number Publication date
CA2571482A1 (en) 2005-12-29
MXPA06015170A (es) 2007-08-21
US20090118316A1 (en) 2009-05-07
JP2008503561A (ja) 2008-02-07
AR049922A1 (es) 2006-09-13
WO2005123191A1 (en) 2005-12-29
EP1765461A1 (en) 2007-03-28
BRPI0512342A (pt) 2008-03-04

Similar Documents

Publication Publication Date Title
WO2005112981A3 (en) Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells
HK1070575A1 (en) Use of botulinum toxin for treating cardiovasculardiseases
NZ595262A (en) Use of il-23 and il-27 antagonists to treat autoimmune ocular inflammatory disease
ATE442592T1 (de) Detektion und/oder beobachtung von synuclein- assoziierten krankheiten
BR0315598A (pt) Anticorpos neutralizantes contra gdf-8 e usos dos mesmos
TW200510349A (en) Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
EP1585963A4 (en) METHOD FOR EVALUATING A MYELOUS SUPPRESSION STATE
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
HUP0102511A2 (hu) Kombinált gyógykezelés bipoláris betegségek kezelésére
HK1108568A1 (en) Method of preventive treatment of allergy by mucosal administration of an allergy vaccine
PL356846A1 (en) Use of interleukin-6 antagonists for the treatment of diseases characterised by high levels of aromatase
NO20024646D0 (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
WO2006041409A8 (en) Medical solution, method for producing and use thereof
EP1543158A4 (en) REGULATED APTAMER THERAPEUTICS
TW200613032A (en) Uses for augmenting bone
ATE447426T1 (de) Elektromagnetische stimulation bei patienten mit osteoporose
WO2003106681A3 (de) Antisense oligonukleotide gegen pim1
TW200738255A (en) Methods of regulating renalase (Monoamine Oxidase C)
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
MXPA04007556A (es) Estimulacion de cpt-1 como medio para reducir peso.
DE60321175D1 (de) Dichloracetat in kombination mit kardioprotektiven oder hämodynamischen medikamenten
HUP0100105A2 (hu) TNF-antagonisták alkalmazása szeptikus betegségek kezelésére szolgáló gyógyszerként
MXPA04011018A (es) Nueva combinacion de inhibidores reversibles de la bomba de protones y productos terapueticos para tratar trastornos de las vias respiratorias.
IL175019A0 (en) Cxcl8 antagonists, their preparation and use
MXPA05013975A (es) Tratamiento de enfermedades asociadas con amiloide y epileptogenesis.